Episode 232: Belzutifan in early and late renal cancer

We’re joined by Toni Choueiri, MD, and Brian Shuch, MD, to
discuss several studies on the use of belzutifan alone and in combination with
other treatments in patients with early and late-stage renal cancer, as well as
patients with Von Hippel-Lindau syndrome and advanced sporadic RCC. Dr. Shuch
is the director of the University of California, Los Angeles’s Kidney Cancer
Program and is the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer
Research. Dr. Choueiri is the director of Dana-Farber Cancer Institute’s Lank
Center for Genitourinary Oncology, and serves as medical director of
Dana-Farber’s International Strategic Initiatives.